These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 15472830

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Systemic preexposure prophylaxis for human immunodeficiency virus infection.
    Romanelli F, Murphy B.
    Pharmacotherapy; 2010 Oct; 30(10):1021-30. PubMed ID: 20874040
    [Abstract] [Full Text] [Related]

  • 4. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM, Merigan TC, Winters MA, Heseltine PN.
    Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
    [No Abstract] [Full Text] [Related]

  • 5. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C, Jiménez-Nacher I, Garrido C, Barreiro P, Poveda E, Corral A, Zahonero N, González-Lahoz J, Soriano V.
    Clin Infect Dis; 2008 Jun 01; 46(11):1782-5. PubMed ID: 18426370
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir.
    Rossi L, Franchetti P, Pierigé F, Cappellacci L, Serafini S, Balestra E, Perno CF, Grifantini M, Caliò R, Magnani M.
    J Antimicrob Chemother; 2007 Apr 01; 59(4):666-75. PubMed ID: 17327293
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-HIV agents. The puzzle of virologic failure with tenofovir.
    TreatmentUpdate; 2004 Apr 01; 16(3):4. PubMed ID: 17216834
    [No Abstract] [Full Text] [Related]

  • 12. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
    Jenny-Avital ER.
    N Engl J Med; 2006 Jun 08; 354(23):2506-8; author reply 2506-8. PubMed ID: 16764056
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR, Morrow JS.
    Clin Infect Dis; 2008 Oct 01; 47(7):984-5. PubMed ID: 18778234
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques.
    Van Rompay KK, Hamilton M, Kearney B, Bischofberger N.
    Antimicrob Agents Chemother; 2005 May 01; 49(5):2093-4. PubMed ID: 15855535
    [Abstract] [Full Text] [Related]

  • 17. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
    Ter Heine R, Huitema AD, Jansen RS, Smits PH, van Gorp EC, Wagenaar JF, Beijnen JH, Mulder JW.
    Antivir Ther; 2009 May 01; 14(2):299-301. PubMed ID: 19430105
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.